Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
SATEEN
A Single-arm Phase II Trial of SAcituzumab Govitecan and Trastuzumab for HER2+ Metastatic Breast Cancer After Trastuzumab dEruxtEcaN (SATEEN)
- NCT06100874 ↗
- Active, not recruiting
- Adrienne G. Waks
- Deep
We haven't built an HCP commentary report on SATEEN (sacituzumab govitecan, trastuzumab and 1 more in Her 2 Positive Breast Cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on SATEEN so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 34 | |
| YouTube | 4 | |
| X videos | 2 | |
| Podcasts | 1 |
The trial
ClinicalTrials.gov- Official title
- A Single-arm Phase II Trial of SAcituzumab Govitecan and Trastuzumab for HER2+ Metastatic Breast Cancer After Trastuzumab dEruxtEcaN (SATEEN)
- Phase
- Phase 2
- Status
- Active, not recruiting
- Conditions
- Her 2 Positive Breast Cancer; Breast Cancer Female; Breast Cancer Metastatic
- Interventions
- Sacituzumab Govitecan; Trastuzumab; Trastuzumab and Hyaluronidase-oysk
- Arms
- Sacituzumab Govitecan + Trastuzumab (or Biosimilar) · Experimental
- Enrollment
- 28
- Primary outcomes
- Overall Response Rate (ORR)
- Sponsor
- Adrienne G. Waks with Gilead Sciences
- Start
- Nov 20, 2023
- Primary completion
- Feb 9, 2026
- Results posted
- No
- Registry record
- NCT06100874 · updated Feb 24, 2026